Drug Profile
Research programme: protein kinase inhibitors - Dynamix Pharmaceuticals/CleveXel Pharma
Alternative Names: CVXL-0074; CVXL-0101; CVXL-0102; DNX-04042; DNX-1000; DNX-4000; DNX-4042; DNX-8000Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Dynamix Pharmaceuticals
- Developer CleveXel Pharma; Dynamix Pharmaceuticals
- Class Small molecules
- Mechanism of Action Janus kinase 3 inhibitors; Polo-like kinase 1 inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Autoimmune disorders; Lymphoma; Rheumatoid arthritis
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in France (PO)
- 28 Dec 2017 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Israel (PO)
- 28 Dec 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in France (PO)